KELVIN POON: Open Payments
NPI 1316581812 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,304 in 307 payments from 19 companies in 2025. Trend: 2023 $2,589 · 2024 $3,713 · 2025 $7,304
Food & beverage: $7,192Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 36 | $919 |
| ABBVIE INC. | 35 | $776 |
| Otsuka America Pharmaceutical, Inc. | 36 | $754 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $753 |
| Alkermes, Inc. | 25 | $562 |
| Janssen Pharmaceuticals, Inc | 11 | $528 |
| Vanda Pharmaceuticals Inc. | 29 | $495 |
| E.R. Squibb & Sons, L.L.C. | 22 | $483 |
| Teva Pharmaceuticals USA, Inc. | 16 | $483 |
| Axsome Therapeutics, Inc. | 15 | $416 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, FANAPT, COBENFY, Auvelity, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
